L&C Medical
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Morrison, Volrick
NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting
4
50
US
Spinosad Topical, Natroba, benzyl alcohol
Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix
Scabies
11/25
03/26
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT06901349: A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Not yet recruiting
2
180
Canada, Japan, US, RoW
Bimagrumab, LY3985863, Tirzepatide, LY3298176, Bimagrumab Placebo, Tirzepatide Placebo
Eli Lilly and Company
Obesity, Overweight
10/26
01/27
NCT06746259: FebriDx® Method Comparison Study Protocol

Recruiting
N/A
800
US
Rapid point of care test to detect host immune response in ARI, Fingerstick test
Lumos Diagnostics, Biomedical Advanced Research and Development Authority
Acute Respiratory Infections (ARIs)
05/25
06/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Morrison, Volrick
NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting
4
50
US
Spinosad Topical, Natroba, benzyl alcohol
Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix
Scabies
11/25
03/26
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT06901349: A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Not yet recruiting
2
180
Canada, Japan, US, RoW
Bimagrumab, LY3985863, Tirzepatide, LY3298176, Bimagrumab Placebo, Tirzepatide Placebo
Eli Lilly and Company
Obesity, Overweight
10/26
01/27
NCT06746259: FebriDx® Method Comparison Study Protocol

Recruiting
N/A
800
US
Rapid point of care test to detect host immune response in ARI, Fingerstick test
Lumos Diagnostics, Biomedical Advanced Research and Development Authority
Acute Respiratory Infections (ARIs)
05/25
06/25

Download Options